Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
Status:
Completed
Trial end date:
2004-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety of gemtuzumab ozogamicin in
relapsed CD33-positive AML patients who received HSCT. If the MTD dose is not reached, 9
mg/m2 will be the maximum tested dose. A secondary objective is to assess efficacy in terms
of the number of patients attaining a complete (CR) or morphological (CRp) remission.